Catalyst Pharmaceuticals Files 8-K/A Amendment
Ticker: CPRX · Form: 8-K/A · Filed: Aug 28, 2025 · CIK: 1369568
| Field | Detail |
|---|---|
| Company | Catalyst Pharmaceuticals, Inc. (CPRX) |
| Form Type | 8-K/A |
| Filed Date | Aug 28, 2025 |
| Risk Level | low |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-statements, exhibits
TL;DR
Catalyst Pharma filed an amendment to its 8-K, updating financial statements/exhibits as of Aug 25, 2025.
AI Summary
Catalyst Pharmaceuticals, Inc. filed an amendment (8-K/A) on August 28, 2025, to its current report originally filed on August 25, 2025. This amendment pertains to financial statements and exhibits, with the date of the earliest event reported being August 25, 2025. The company is incorporated in Delaware and its principal executive offices are located in Coral Gables, Florida.
Why It Matters
This filing indicates an update or correction to previously submitted financial statements or exhibits, which could be important for investors assessing the company's financial health and disclosures.
Risk Assessment
Risk Level: low — This is a routine amendment to a previous filing, likely for administrative or minor correction purposes, rather than a significant event.
Key Players & Entities
- CATALYST PHARMACEUTICALS, INC. (company) — Registrant
- August 25, 2025 (date) — Date of Earliest Event Reported
- August 28, 2025 (date) — Filing Date
- Delaware (jurisdiction) — State of Incorporation
- Coral Gables, Florida (location) — Principal Executive Offices
FAQ
What is the purpose of this 8-K/A filing?
This 8-K/A filing is an amendment to a previously filed current report, specifically concerning financial statements and exhibits.
When was the earliest event reported in this filing?
The earliest event reported in this filing was on August 25, 2025.
What is the filing date of this amendment?
This amendment was filed on August 28, 2025.
In which state is Catalyst Pharmaceuticals, Inc. incorporated?
Catalyst Pharmaceuticals, Inc. is incorporated in Delaware.
Where are the principal executive offices of Catalyst Pharmaceuticals, Inc. located?
The principal executive offices of Catalyst Pharmaceuticals, Inc. are located at 355 Alhambra Circle, Suite 801, Coral Gables, Florida, 33134.
Filing Stats: 628 words · 3 min read · ~2 pages · Grade level 10.4 · Accepted 2025-08-28 16:30:37
Key Financial Figures
- $0.001 — Ticker Symbol Common Stock, par value $0.001 per share NASDAQ Capital Market CPRX
Filing Documents
- d40349d8ka.htm (8-K/A) — 26KB
- d40349dex991.htm (EX-99.1) — 8KB
- 0001193125-25-191273.txt ( ) — 165KB
- cprx-20250825.xsd (EX-101.SCH) — 44KB
- d40349d8ka_htm.xml (XML) — 5KB
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits 99.1 Press release issued by the Company on August 26, 2025. 104 Cover Page Interactive Data File (embedded within the Inline XBRL document) 2
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. Catalyst Pharmaceuticals, Inc. By: /s/ Michael W. Kalb Michael W. Kalb Executive Vice President and Chief Financial Officer Dated: August 28, 2025 3